First Approval For Clinical Testing Of COVID-19 Vaccine In Germany Granted
First tests are to be carried out on healthy volunteers. However, experts do not expect a finished vaccine to be available before the end of the year.
The Paul Ehrlich Institute announced today that it has approved the start of clinical trials for four possible COVID-19 vaccines.
All four possible vaccines were developed by the biotechnology company BioNTech in Mainz.
Founded in 2008, the company specializes in the development and production of agents used in individualized immunotherapy for cancer. BioNTech focuses on drugs that are mRNA-based.
The vaccines now approved for testing are also based on this approach. These are, therefore, mRNA-based vaccines.
Germany thus joins the ranks of nations in which clinical testing of vaccines against COVID-19 is carried out.
In the first phase, the drugs will initially be tested exclusively on healthy test persons. Only when this phase has been successfully completed, will phase two follow, which will be carried out on high-risk patients.
The tests are expected to last between three and five months.
Before approval, the basic tolerability of the substances was already tested on mice. These tests have also provided initial findings on the presumed vaccine doses required.
Nevertheless, experts do not expect a vaccine to be available before 2021.
Sources
René Junge a published author writing on ILLUMINATION.
Do you want more of this?
Receive weekly emails, and don’t miss any of my articles.
subscribe here http://bit.ly/ReneJunge
Read also:
